Lead Product(s) : Caficrestat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Applied Therapeutics Announces Topline Results from ARISE-HF Phase 3 Study of AT-001
Details : AT-001 (caficrestat) is an investigational oral, novel, potent Aldose Reductase inhibitor which is in Phase 3 clinical development for the treatment of Diabetic Cardiomyopathy.
Brand Name : AT-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2024
Lead Product(s) : Caficrestat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?